I Introduction
Medicinal products are granted market authorisation only after extensive assessment of their quality, safety and efficacy. Nevertheless, all medicines might produce adverse drug reactions (ADRs), which are only detected after authorised products are being rolled-out to the market.Footnote 1 In the past, EU regulation used to rely primarily on pre-marketing assessment and authorisation for establishing risks and benefits before the marketing of medicinal products.Footnote 2 This has changed since the 1990s and today, drug development and manufacturing, clinical trials, market authorisation and pharmacovigilance are regulated in the EU. Pharmacovigilance refers to the collection and continued evaluation of data on ADRs, ex-post risk management and communication with relevant stakeholders and the public. The emphasis on monitoring and ex-post risk management signifies an important shift in EU regulation towards pharmacovigilance.Footnote 3 The foundation of pharmacovigilance related activities is the timely and accurate reporting of ADRs by market authorisation holders, healthcare professionalsFootnote 4 and increasingly patients.
The EU system of pharmacovigilance is based on Directive 2001/83/EC, which codified hitherto separate pieces of legislation in a single directive. However, an assessment of the directive found national inconsistencies due to non-optimal compliance with existing rules.Footnote 5 The European Commission estimated that ADRs account for 5% of all hospital admissions and that ADRs are the fifth most common cause of hospital related deaths.Footnote 6 As a result, the Commission initiated a reform of the EU pharmacovigilance system which led to the adoption of Directive 2010/84/EU, which complements Directive 2001/83/EC.Footnote 7 The reform aims at a better protection of public health by extending the requirements for Member States with regard to national pharmacovigilance systems and in particular ADR reporting.Footnote 8 In August 2016, the Commission released a report on the pharmacovigilance related activities of Member States and the European Medicines Agency (EMA), indicating that the reform has indeed brought about improvements, with the number of ADR reports increasing.Footnote 9
While acknowledging these improvements, ample room for concern remains. The present article presents a critical assessment of the current ADR reporting in the EU and its Member States. It examines the latest pharmacovigilance reform, identifying serious challenges of practical implementation at the national level.Footnote 10 One of the key problems is underreporting of ADRs by both healthcare professionals and patients. Therefore, extending the legal requirements on ADR reporting for Member States will simply not do the trick. To be more effective, substantial changes regarding the practice of ADR reporting in Member States are needed. The potential of such changes, however, is constrained by institutional factors and national healthcare policies. These policies, as well as the national pharmacovigilance systems, are characterised by significant variation.
II Analysis
The evidence presented in this analysis is based on a comparative case study of national pharmacovigilance systems in six EU Member States: Germany, Poland, Portugal, France, Finland and the UK. The case selection is based on ideal-type healthcare systems. These systems are characterised by essentially three dimensions: the financing of health services, the type of healthcare provision and the regulatory type. The selected countries cover the range of ideal-type state healthcare system (UK), state-based mixed type (Finland, Poland, France) and societal-based mixed type (Portugal, Germany). National regulatory authorities, stakeholder organisations and healthcare professionals have been identified as key informants with regard to ADR reporting. Hence, the analysis is informed by secondary sources as well as in-depth, qualitative interviews with stakeholders in the national pharmacovigilance systems. In total, 33 interviews, either face-to-face or by telephone, were conducted between April and September 2016. Evidence presented in the following analysis, and not otherwise attributed, is based on these primary sources.
1 Reporting of ADRs under Directive 2010/84/EU: legal requirements
During the legislative procedure leading to the adoption of Directive 2010/84/EU, the provisions on ADR reporting proved to be a controversial subject among Member States.Footnote 11 Based on Articles 101 and 102 of Directive 2010/84/EU, Member States shall operate national pharmacovigilance systems and shall “take all appropriate measures to encourage patients, doctors, pharmacists and other healthcare professionals to report suspected adverse reactions to the national competent authority; for these tasks, organisations representing consumers, patients and healthcare professionals may be involved as appropriate”Footnote 12 ; the Member States shall “facilitate patient reporting through the provision of alternative reporting formats in addition to web-based formats”.Footnote 13
Throughout the procedure, the exact wording of these provisions was subject to much discussion among Member States, with seemingly minuscule changes requested. For the first time, due to an amendment of the legislative text by the European Parliament, patients are recognised as relevant actors in national pharmacovigilance systems. Whereas market authorisation holders are established actors in such systems, the pharmacovigilance reform particularly extended provisions with regard to ADR reporting by healthcare professionals and patients. The reporting of ADRs by patients is often perceived to be essential for effective pharmacovigilance. Given the emphasis on monitoring and ex-post regulation of medicines, the involvement of patients raises a number of economic and ethical questions.Footnote 14
The 2016 Commission report on pharmacovigilance related activities of the Member States highlights the fact that patient reporting has increased significantly since the directive came into effect.Footnote 15 However, a large portion of this increase is due to the introduction of reporting systems in Member States that hitherto did not have such systems for patient reporting. Furthermore, after a sharp increase in mid-2012, the number of reports stagnates and the curve flattens out towards the end of the reporting period. Despite the increase of reported ADRs, the implementation of this provision is characterised by underreporting of patients across Member States.Footnote 16
2 Reasons for underreporting by patients and healthcare professionals
Since patient reporting is comparably new in many Member States, they simply lack the awareness regarding their role in pharmacovigilance. Therefore, European, national and regional authorities need to invest more in awareness-raising campaigns to increase public knowledge about ADR reporting. Yet only a third of all Member States have resources dedicated to awareness-raising and healthcare professionals are still the main target group of awareness-raising campaigns.Footnote 17 It has been suggested that the use of mobile digital applications and social media might increase ADR reporting by patients, yet it also raises serious technical, regulatory and ethical questions.Footnote 18 In the EU, only two Member States have mobile applications and social media available for ADR reporting.Footnote 19 There is significant variation across Member States. Whereas the UK has introduced a “Yellow Card App” for mobile ADR reporting, patients in Finland are required to report through regular mail.
Although healthcare professionals are established actors in pharmacovigilance, underreporting is still prevalent among doctors, nurses and pharmacists. It is estimated that only 1–10% of serious ADRs are reported.Footnote 20 Article 102 allows Member States to impose specific obligations on healthcare professionals to report ADRs, yet healthcare professionals are not legally obliged in all national pharmacovigilance systems. Instead, reporting is often based on professional codes of conduct only. Regardless of the legal foundation, ADR reporting is often perceived by healthcare professionals to be time-consuming and incompatible with other tasks. Moreover, the occurrence of ADRs is often seen by healthcare professionals as failures associated with the perceived loss of reputation. Adding to this professional liability, legal liability presents an important impediment to ADR reporting in case individual healthcare professionals can be legally held responsible.
The latest reform of the EU pharmacovigilance system appears to be a missed opportunity in this respect. Article 101 of Directive 2010/84/EU was extended to include the reporting of adverse effects due to “use outside the terms of the marketing authorisation”.Footnote 21 Hence, the reform extended the requirements for Member States’ pharmacovigilance system to ADR reporting as a result of medication errors. In contrast to non-preventable effects because of the inherent limitations of pre-marketing assessment, adverse effects as a result of medication errors can be prevented. During the legislative procedure, the European Parliament aimed to amend Article 102 by stating that “reporting of suspected adverse reactions due to medication errors should be on a “no blame” basis, and should be legally privileged”.Footnote 22 It is recommended to exempt healthcare professionals from legal liability since this would increase ADR reporting.Footnote 23 The amendment was rejected by the Council, because it would imply a radical overhaul of established legal principles in some Member States.
In the six Member States analysed, healthcare professionals in Poland, France and Portugal have indicated that legal liability is an important challenge for ADR reporting. However, legal principles are not the only constraint for effective implementation with regard to ADR reporting as a result of medication errors. In some Member States, there is a widespread misconception that ADRs only occur in case of medication errors. Therefore, healthcare professionals do not report ADRs for fear of damaging their reputation. Hence, extending the legal requirements of a reformed EU pharmacovigilance system is not sufficient. Rather, substantial changes regarding the practice of ADR reporting are needed at the individual level, thus focusing on healthcare professionals.
Besides extensive fear of reputational or legal liability, many healthcare professionals across the EU appear to be rather unaware of the importance of ADR reporting for drug safety, leading to a wrong prioritisation of tasks. In order to increase ADR reporting in the short-term, awareness-raising campaigns among healthcare professionals regarding the importance of pharmacovigilance are therefore advisable. In addition, advanced post-graduate training on a regular basis is needed to ensure that healthcare professionals acquire the necessary skills for coping with the complex task of ADR reporting. This includes encouraging and assisting patients with high-quality reporting as well as legal counselling to alleviate healthcare professionals’ fear of legal liability. Since ADR reporting is not an integral part of healthcare professionals’ curricular in all Member States, substantial, long-term changes will only be made if pharmacovigilance becomes mandatory for every medical and pharmacy student. This is of particular importance with regard to biological medicines, which due to their technical specificities pose additional challenges to the practice of ADR reporting.Footnote 24
III Pharmacovigilance in the context of national healthcare systems and institutional constraints of ADR reporting
Apart from legal requirements regarding ADR reporting of healthcare professionals, lack of time and skills are common challenges with regard to the effective implementation of pharmacovigilance in the EU. Awareness-raising campaigns, mandatory courses on pharmacovigilance and advanced post-graduate training are essential remedies to these challenges with a view to substantial changes regarding the practice of ADR reporting at the individual level of healthcare professionals. However, healthcare professionals are not isolated actors, and institutional factors impede or facilitate the effective implementation of pharmacovigilance measures. For instance, the perception of ADRs being a sign of failure and the perceived loss of reputation can only be addressed by introducing a different culture of care and patient safety in which ADR reporting is seen as a key responsibility of healthcare professionals. This might require a certain change of norms and values represented by and within healthcare institutions, which also need to facilitate ADR reporting through streamlined internal processes.
However, the institutional level in itself is embedded in national healthcare policies and the problem of underreporting has to be seen in the varying contexts of national pharmacovigilance systems. Some Member States have centralised systems of pharmacovigilance, and others have de-centralised systems; some Member States have separate systems for biological medicines, while others do not. In general, national regulatory authorities and healthcare institutions should receive sufficient financial resources, thus alleviating the burden of individual healthcare professionals and facilitating ADR reporting. Yet the economic crisis and the scarcity of resources is an important impediment in some Member States. Furthermore, Member States need to further the cooperation of all relevant actors with the national pharmacovigilance system, yet problems and potentials of such cooperation will vary depending on the institutional structure of national health policies and general features of the national political system. In Germany, for instance, pharmacovigilance is often hindered by strict data protection laws, which restrict access to information held by statutory health insurances.Footnote 25
In a similar vein, pharmacovigilance should receive a more prominent role in the education of healthcare professionals, be they doctors, pharmacists or nursing staff. Cultural changes at the institutional level in hospitals and other healthcare providers can only be internalised by healthcare professionals if the underlying values and benefits of ADR reporting are included in the curricula of universities and other training facilities. Yet again, long-term changes require substantial reform of national healthcare policies, going beyond the mere implementation of the EU pharmacovigilance system.
Another case in point is the question of legal liability which has to balance patients’ rights and the effectiveness of ADR reporting. In this respect, the Council of Europe put forward a number of recommendations to improve patient safety and prevent adverse events in healthcare.Footnote 26 Regarding ADR reporting, the recommendations are very similar to the provisions enshrined in Article 102 of Directive 2010/84/EU. However, the recommendations are based on a no-fault approach in which patients’ rights ought to be accommodated with the requirements of extensive ADR reporting. Training and legal counselling of healthcare professionals at the individual level thus needs to be compensated by policies adopted by Member States, for instance by strengthening confidentiality or setting up compensation schemes for patients’ claims.
IV Conclusion
The present article examined ADR reporting in the EU after the latest pharmacovigilance reform (Directive 2010/84/EU). It critically assessed the challenges of effective practical implementation across Member States. Recent assessments indicate that the reform has indeed brought about improvements with the number of ADRs increasing.Footnote 27 Nevertheless, legal provisions laid down in Article 102 of Directive 2010/84/EU are not implemented without problems leading to underreporting of ADRs by both healthcare professionals and patients. On the one hand, patients simply lack the awareness regarding their role in pharmacovigilance, and on the other hand, healthcare professionals often lack time and skills to report ADRs. Furthermore, healthcare professionals are not always legally obliged to report. Often professional norms as well as legal ramifications prevent them from doing so.
Hence, extending the requirements for Member States with regard to ADR reporting is not sufficient and instead substantial changes regarding the practice of ADR reporting are necessary. Since these changes have to be internalised by healthcare professionals, they require a change of norms and values within healthcare institutions. In this respect, looking beyond the field of healthcare, for instance at aviation, offers new perspectives on how risks related to adverse drug reactions can be regulated.Footnote 28 The emphasis on curricula and training and a “no blame” reporting culture are some of the lessons that can be drawn from aviation safety.Footnote 29 There are, however, limits to lesson-drawing due to the idiosyncrasies of the healthcare sector and the persisting differences of national healthcare policies. Since national healthcare policies might be constraining legal and normative change in terms of ADR reporting, one has to be cautious when deriving expectations regarding the effectiveness of practical implementation of current and future reform of pharmacovigilance in the EU. National variation is likely to remain characteristic of the EU pharmacovigilance system.
